TIGIT / NFAT Reporter - Jurkat Cell Line

Catalog #
60538
$10,855 *
Size: 2 vials
Qty
*US Pricing only. For international pricing, please contact your local distributor.
Purchase
Description

Recombinant Jurkat T cells stably transfected to express both the firefly luciferase gene under the control of NFAT response elements, and human TIGIT (V-set and immunoglobulin domain-containing protein 9, VSIG9, V-set and transmembrane domain-containing protein 3, and VSTM3, GenBank Accession No. NM_173799).

TIGIT / NFAT Reporter - Jurkat Cell Line

Interested in screening and profiling inhibitors, blocking antibodies, or activators of TIGIT without the need to purchase and license the cell line? Check out our Cell Signaling Pathway Screening.

Purchase of this cell line is for research purposes only; commercial use requires a separate license. View the full terms and conditions.

Synonyms
T-cell immunoreceptor with Ig and ITIM domains, V-set and immunoglobulin domain-containing protein 9, VSIG9, V-set and transmembrane domain-containing protein 3, VSTM3
Product Info
Storage and Usage
Citations
Host Cell Line
Jurkat
Materials Required But Not Supplied

For Culture:

Thaw Medium 2 (BPS Cat. #60184)
Growth Medium 2A (BPS Cat. #60190)

For Assay:

• CD155/TCR Activator-CHO cell line (BPS Cat. # 60548)
Assay Medium 3A (BPS Cat. #79816)
• Thaw Medium 3 (BPS Cat. #60186): Ham’s F-12 medium (Hyclone, #SH30526.01) supplemented with 10% FBS (Life Technologies #26140-079), 1% Penicillin/Streptomycin (Hyclone, #SV30010.01)
• Anti-TIGIT neutralizing antibody (BPS Cat. # 71340)
• 96-well tissue culture-treated white clear-bottom assay plate
• One-Step luciferase assay system (BPS Cat. # 60690) or other luciferase reagents for measuring firefly luciferase activity
• Luminometer

UniProt #
Q495A1
Mycoplasma Testing
The cell line has been screened using the PCR-based Venor®GeM Mycoplasma Detection kit (Sigma-Aldrich) to confirm the absence of Mycoplasma species.
Background
TIGIT is a co-inhibitory receptor that is highly expressed in Natural Killer (NK) cells, activated CD4+, CD8+ and regulatory T cells. Interaction with the poliovirus receptor (PVR; CD155) on antigen presenting cells, such as dendritic cells, recruits Src homology (SH) domain-containing protein tyrosine phosphatase SHP1 and SHP2 or the inositol phosphatase SHIP1 and SHIP2 to the TIGIT ITIM domain. This increases IL-10 release and suppresses NF-kB and NFAT T cell receptor (TCR) signaling, which blocks T cell proliferation and cytokine production. It serves as a competitive inhibitor of CD226, a co-stimulatory receptor for CD155. TIGIT targeting antibodies that block this T cell-intrinsic inhibitory effects have shown enhanced anti-tumor and anti-viral functions in preclinical studies.
References

1. Li M et.al. (2014) T-cell Immunoglobulin and ITIM Domain (TIGIT) Receptor/ Poliovirus Receptor (PVR) Ligand Engagement Suppresses Interferon-g Production of Natural Killer Cells via b-arrestin 2-mediated Negative Signaling. J Biol Chem. 289: 17647- 17657.
2. Stanietsky N. et.al. (2009) The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity. PNAS. 106: 17858-17863.
3. Zhu et.al. (2016) Identification of CD112R as a novel checkpoint for human T cells. J Exp. Med. 213: 167-176.
4. Yu X. et.al. (2008) The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells. Nat.Immunol. 10: 48-57.